Talazoparib (Talzenna)

Description

Talazoparib is a potent PARP inhibitor that has shown activity in colorectal cancer patients with specific genetic alterations, particularly those with homologous recombination deficiency or BRCA mutations. In CRC, this targeted therapy is utilized in patients whose tumors harbor DNA repair defects that make them vulnerable to PARP inhibition. The drug works by exploiting synthetic lethality in cancer cells that already have compromised DNA repair mechanisms.

Mechanism of Action

Talazoparib selectively inhibits poly(ADP-ribose) polymerase (PARP) enzymes, particularly PARP-1 and PARP-2, which are essential for single-strand DNA break repair. By blocking PARP function, the drug prevents repair of DNA damage, leading to accumulation of double-strand breaks that are lethal to cancer cells with defective homologous recombination repair pathways. This creates a synthetic lethal interaction that preferentially kills tumor cells while sparing normal cells with intact DNA repair mechanisms.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials